Navigation Links
OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
Date:5/11/2009

BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final survival data from a randomized Phase 2 trial evaluating OGX-011 in combination with docetaxel versus docetaxel alone as first-line chemotherapy in patients with metastatic castration-resistant prostate cancer will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, Phase 1 clinical data evaluating OncoGenex' second product candidate, OGX-427, will also be featured in an oral presentation at ASCO.

Abstracts will be made available to the public online on ASCO's website, www.ASCO.org, on Thursday, May 14 at 6:00 p.m. (EDT).

The oral presentations are scheduled for Saturday, May 30 at the ASCO meeting in Orlando, Florida. These formal presentations will also include new data that has been updated since abstracts were submitted to ASCO.

Abstract Presentation Information

    Title:    Mature results of a randomized phase II study of OGX-011 in
              combination with docetaxel/prednisone versus
              docetaxel/prednisone in patients with metastatic castration
              resistant prostate cancer
    Authors:  K. N. Chi, S. J. Hotte, E. Yu, D. Tu, B. Eigl, I. Tannock,
              F. Saad, S. North, J. Powers, E. Eisenhauer, National Cancer
              Institute of Canada Clinical Trials Group
    Date:     4:30 p.m. - 4:45 p.m. EDT, Saturday, May 30, 2009
    Location: Level 3, Chapin Theatre, W320, Orange County Convention Center
    Abstract: # 5012

    Title:    OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO),
              against HSP27: Results of a first-in-human trial
    Authors:  S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S. H
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports First Quarter Financial Results
2. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
3. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
5. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
6. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
7. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
8. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
9. OncoGenex Reports Third Quarter Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
11. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
(Date:1/14/2014)... 2014 Holloway America today announced an ... test reports (MTRs) for all pressure vessels and tank ... is particularly important for equipment that must meet ASME, ... features search functionality that allows authorized users to quickly ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... , May 4 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ... studies with ANAVEX 2-73, the company,s lead compound for the treatment ... , , ... class of drugs that target mitochondrial dysfunction thought to be caused ...
... Packing Record Tetrahedral dice, which have four ... yet tested, according to research performed by a collaboration ... revelation is the result of a series of experiments ... and adding more dice until the containers were completely ...
... , , , ... EDMONTON, AB , May 3 /PRNewswire-FirstCall/ - ... strategy. The Company,s new strategy will encompass becoming a full ... invest in and advise companies on strategy, financing, mergers & ...
Cached Biology Technology:Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 3Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 4Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 5Densest dice packing and computing with molecules 2BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3
(Date:4/16/2014)... eyes up, and you cannot lift your upper eyelid. You walk ... look straight when they are rolled down in the eye socket. ... normal position of their head. In order to correct this condition, ... paper published in the April 16 print issue of the journal ...
(Date:4/16/2014)... Biosciences Division of Lawrence Berkeley National Laboratory (Berkeley Lab) ... authority on the evolutionary design principles of cellular networks ... biology, has been named one of six recipients of ... Secretary Ernest Moniz. The E.O. Lawrence Award, the Department ...
(Date:4/16/2014)... Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of ... Freiburg have discovered the receptor responsible for smuggling the toxin ... The TpeL toxin, which is formed by C. perfringens ... It is very similar to the toxins of many other ...
Breaking Biology News(10 mins):Researchers track down cause of eye mobility disorder 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3Gate for bacterial toxins found 2
... July 6 Delays in cargo screening significantly extend ... be shortened with foolproof and rapid screening and detection ... smuggling augment the need for efficient access control systems ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , New analysis from ...
... , WASHINGTON, July 7 Eight supply chain professionals were ... organization,s Board of Directors, joining the seven existing members of SCC,s board. ... through June 30, 2012, are as follows: , , , ... CTO, Manufacturing & Distribution Industries, Hewlett Packard , ...
... , , LONDON, July 10 IBM (NYSE: ... executive agency of the UK Home Office, have signed a seven-year agreement ... upgrade to biometric passports and enhance the security of the UK border. ... (UKBA) Immigration and Asylum Fingerprint System (IAFS) which holds biometrics collected from ...
Cached Biology News:Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 2Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 3UK Identity and Passport Service and IBM Sign 7-year National Biometric Identity Service (NBIS) Contract 2
... culture or fermentation is the ability to ... make rapid adjustments in response to changes ... provide immediate analysis of key nutrients, metabolites, ... media. BioProfile analyzers are fully automated, multi-test ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
... sequence corresponds to residues 115-133 of rat SAP97. The sequence ... L - P - S - E - R - I ... N - E - V - L - G - P ... conjugation and is not a part of the native rat SAP97 ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
Biology Products: